Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety (Journal article)

Lazaridis, G./ Pentheroudakis, G./ Pavlidis, N.

Neoadjuvant chemotherapy is used in non-metastatic breast cancer in order to eradicate micrometastatic deposits early during disease course, as well as in order to decrease tumour bulk and render surgery feasible or breast-conserving. Moreover, it offers promise to serve as an in vivo chemosensitivity assay and as a powerful predictive factor for outcome. Trastuzumab, a monoclonal antibody targeting an epitope in the extracellular domain of the Human Epidermal Growth Factor Receptor-2 (HER2/erbB-2), was found to be active in HER2-overexpressing metastatic as well as in resected breast cancer when given post-operatively. In this review, we summarise the evidence on the activity and safety of trastuzumab-containing neoadjuvant chemotherapy for the management of women with localised, irresectable or resectable breast cancer. Twenty-three published studies enrolling a total of 585 patients reported pathologic complete responses (pCR) ranging from 7 to 78% with a favourable adverse event profile, data that are presented and discussed in this review. The impact of trastuzumab on long-term outcome, the identification of surrogate biomarkers for sensitivity or resistance to antineoplastic therapy, the optimal schedule of trastuzumab administration and the more active chemotherapeutic regimen for synergism are only a few of the key points needing elucidation so as to rationalise trastuzumab-based approaches.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Antibodies, Monoclonal/*therapeutic use,Antibodies, Monoclonal, Humanized,Antineoplastic Agents/*therapeutic use,Antineoplastic Combined Chemotherapy Protocols/therapeutic use,Breast Neoplasms/chemistry/*drug therapy,Clinical Trials as Topic,Drug Synergism,Female,Humans,Neoadjuvant Therapy,Receptor, erbB-2/analysis
URI: https://olympias.lib.uoi.gr/jspui/handle/123456789/20729
ISSN: 1040-8428
Link: http://www.ncbi.nlm.nih.gov/pubmed/17766143
http://ac.els-cdn.com/S1040842807001576/1-s2.0-S1040842807001576-main.pdf?_tid=5a63ecbd6f0bc3a8a7cd2749281bd4da&acdnat=1333954257_8b29b9c8fb8c15ebe76a65cb676411cb
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Lazaridis-2008-Integrating trastuzu.pdf161.07 kBAdobe PDFView/Open    Request a copy


 Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20729
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.